2024
Renal Angptl4 is a key fibrogenic molecule in progressive diabetic kidney disease
Srivastava S, Zhou H, Shenoi R, Morris M, Lainez-Mas B, Goedeke L, Rajendran B, Setia O, Aryal B, Kanasaki K, Koya D, Inoki K, Dardik A, Bell T, Fernández-Hernando C, Shulman G, Goodwin J. Renal Angptl4 is a key fibrogenic molecule in progressive diabetic kidney disease. Science Advances 2024, 10: eadn6068. PMID: 39630889, PMCID: PMC11616692, DOI: 10.1126/sciadv.adn6068.Peer-Reviewed Original ResearchConceptsAngiopoietin-like 4Diabetic kidney diseaseIntegrin B1Fibrogenic moleculesMutant miceSTING pathway activationIncreased fatty acid oxidationProgressive diabetic kidney diseaseDiabetic kidneyKidney diseaseReduced epithelial-to-mesenchymal transitionEpithelial-to-mesenchymal transitionFatty acid oxidationExpression of pro-inflammatory cytokinesTargeted pharmacological therapiesGene expressionMitochondrial damageEndothelial-to-mesenchymal transitionPro-inflammatory cytokinesPathway activationPharmacological therapyControl miceIntegrinAcid oxidationFibrogenic phenotypeThe mouse metabolic phenotyping center (MMPC) live consortium: an NIH resource for in vivo characterization of mouse models of diabetes and obesity
Laughlin M, McIndoe R, Adams S, Araiza R, Ayala J, Kennedy L, Lanoue L, Lantier L, Macy J, Malabanan E, McGuinness O, Perry R, Port D, Qi N, Elias C, Shulman G, Wasserman D, Lloyd K. The mouse metabolic phenotyping center (MMPC) live consortium: an NIH resource for in vivo characterization of mouse models of diabetes and obesity. Mammalian Genome 2024, 35: 485-496. PMID: 39191872, PMCID: PMC11522164, DOI: 10.1007/s00335-024-10067-y.Peer-Reviewed Original ResearchMouse Metabolic Phenotyping CentersMouse model of diabetesModels of diabetesNational Institutes of HealthNational Institute for DiabetesDigestive and Kidney DiseasesBehavioral phenotyping testsRenal functionProcedure in vivoFood intakeIn vivo characterizationMouse modelHeterogeneity of diabetesKidney diseaseBody compositionPhenotyping CentersInstitutes of HealthMiceObesityDiabetesPhenotypic testsWhole-body carbohydrateInsulin actionLipid metabolismLiving mice
2020
220-LB: Glucagon Promotes Hepatic Autophagy by AMPK-Mediated mTORC1 Inhibition
GALSGAARD K, WEWER ALBRECHTSEN N, HOLST J, SHULMAN G, PETERSEN K, NASIRI A, CLINE G, ZHANG X, LEE J, HUBBARD B. 220-LB: Glucagon Promotes Hepatic Autophagy by AMPK-Mediated mTORC1 Inhibition. Diabetes 2020, 69 DOI: 10.2337/db20-220-lb.Peer-Reviewed Original ResearchSpouse/partnerDohme Corp.Hepatic autophagyMerck SharpKidney diseaseNovo Nordisk A/SAMP kinaseGlucagon treatmentPlasma glucagon concentrationsAdvisory PanelKrebs-Henseleit bicarbonate bufferHepatic protein metabolismNational InstituteNovo Nordisk FoundationMarkers of autophagyHepatic glucose metabolismFasted male ratsProtein/amino acid metabolismGlucagon's roleGlucagon concentrationsGlucagon infusionMale ratsAwake miceNovo Nordisk A/S.Glucose metabolism